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ABSTRACT
Objective To determine the prevalence of upregulation
of interferon (IFN) type I inducible genes, the so called
‘IFN type I signature’, in CD14 monocytes in 69 patients
with primary Sjögren’s syndrome (pSS) and 44 healthy
controls (HC) and correlate it with disease manifestations
and expression of B cell activating factor (BAFF).
Methods Expression of IFI44L, IFI44, IFIT3, LY6E and
MX1 was measured using real time quantitative PCR in
monocytes. Expression values were used to calculate IFN
type I scores for each subject. pSS patients positive for
the IFN type I signature (IFN score≥10) and patients
negative for the signature (IFN score<10) were then
compared for clinical disease manifestations and BAFF
expression. A bioassay using a monocytic cell line was
performed to study whether BAFF mRNA expression was
inducible by IFN type I activity in serum of patients with
pSS.
Results An IFN type I signature was present in 55% of
patients with pSS compared with 4.5% of HC. Patients
with the IFN type I signature showed: (a) higher EULAR
Sjögren’s Syndrome Disease Activity Index scores; higher
anti-Ro52, anti-Ro60 and anti-La autoantibodies; higher
rheumatoid factor; higher serum IgG; lower C3, lower
absolute lymphocyte and neutrophil counts; (b)higher
BAFF gene expression in monocytes. In addition, serum
of signature-positive patients induced BAFF gene
expression in monocytes.
Conclusions The monocyte IFN type I signature
identifies a subgroup of patients with pSS with a higher
clinical disease activity together with higher BAFF mRNA
expression. Such patients might benefit from treatment
blocking IFN type I production or activity.
INTRODUCTION
Primary Sjögren’s syndrome (pSS) is an auto-
immune disease characterised by lymphocytic
infiltrates in salivary and lachrymal glands. After
rheumatoid arthritis, pSS is the second most
common generalised autoimmune disease.1
Nevertheless, establishment of the diagnosis is dif-
ficult owing to heterogeneity of the disease and
lack of a specific diagnostic test. The diagnosis of
pSS is based on 2002 American–European classifi-
cation criteria.2 Treatment is mainly symptomatic
and the efficacy differs across patients. If new
biomarkers based upon underlying pathogenic
pathways can be identified, then more effective,
evidence-based treatments for pSS might be
developed.
Previously, we were the first to describe a sys-
temic upregulation of interferon (IFN) type I indu-
cible genes in CD14 monocytes of patients with
pSS.3 This was in line with the described local
increased activation of IFN type I in salivary
glands of patients with pSS4–6 and confirmed in
peripheral blood mononuclear cells (PBMCs).7 IFN
type I has an important role in the innate immun-
ity by inhibiting viral replication, activating
natural killer cells, boosting generation and activa-
tion of dendritic cells and enhancing antibody
responses.8–12 Given that there are 17 different IFN
type I subtypes, however, it is difficult to measure
protein levels using an ELISA. For diseases such as
hepatitis C, IFN type I is part of the conventional
treatment. Interestingly, development of
Sjögren-like symptoms has been described upon
treatment with IFN type I in patients with hepa-
titis C13–15 supporting the role for IFN type I in
the pathogenesis of pSS.
Another factor known to be involved in the
pathogenesis of pSS is B cell activating factor
(BAFF) of the tumour necrosis factor family. An
increased expression of BAFF, which correlates
with autoantibody level, in both serum16 17 and
salivary glands,18 has been described for pSS.16
BAFF-transgenic mice develop Sjögren-like symp-
toms.19 IFN type I has been shown to induce
BAFF expression in cultured monocytes and saliv-
ary gland epithelial cells of patients with pSS20 21
and a correlation between IFN type I and BAFF
has been shown in patients with multiple sclerosis
treated with IFN type I.22 BAFF dependence of
IFN type I functioning mechanisms has been
observed in systemic lupus erythematosus
(SLE)-prone mice.23
Previously, we found a significant upregulation
of 23 IFN type I inducible genes using whole
genome analysis of pooled monocyte samples of
patients with pSS. Further assessment of the
prevalence of the monocyte IFN type I inducible
gene overexpression in pSS and correlations with
disease manifestations have yet to be performed.
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In this study, we therefore first measured the expression of 11
IFN type I inducible genes, which were previously detected by
us, in CD14 monocytes from 69 patients with pSS and 44
healthy controls (HC). Results of factor analysis showed that
five genes (IFI44, IFI44L, IFIT3, LY6E and MX1) explained 95%
of the total variance of the 11 genes, and we therefore decided
to adopt overexpression of these five genes as our operational
definition of positivity for an ‘IFN type I signature’. The rela-
tionship between this IFN type I signature in monocytes and
various disease manifestations was then studied. Given the
data suggesting that BAFF is an IFN type I inducible factor, we
further decided to measure the in vivo BAFF mRNA expression
in monocytes of patients with pSS and to correlate the expres-
sion level with the IFN type I signature.
PATIENTS AND METHODS
Patients
Sixty-nine patients with a positive diagnosis for pSS according
to 2002 American–European criteria2 were recruited. Patients
treated with prednisone >10 mg daily, immunosuppressant or
biological agents were excluded. The level of disease activity was
assessed using EULAR Sjögren’s Syndrome Disease Activity
Index (ESSDAI).24 Forty-four HC with no autoimmune diseases
and not using corticosteroids were included. Characteristics of
patients and controls are summarised in table 1. The medical
ethical review committee of the Erasmus MC approved the
study and written informed consent was obtained.
Blood collection and isolation of monocytes
Blood was collected in clotting tubes for serum preparation
(stored at −80°C) and in sodium-heparin tubes for PBMC prep-
aration, as described previously.25 CD14-positive monocytes
were isolated as described.25
Real-time quantitative-PCR (RQ-PCR)
Total RNA was isolated from purified monocytes followed by
cDNA preparation and RQ-PCR analysis using predesigned
primer/probe sets (Applied Biosystems, Foster City, California,
USA).25 For calculation of relative expression, all samples were
normalised against expression of the household gene Abl.26 Fold
change values were determined from normalised CT values
using 2−ΔΔCT method (User Bulletin, Applied Biosystems).
Measurement of complement, immunoglobulin levels and
autoantibodies
C3 and C4 were measured using Immage nephelometer
(Beckman Coulter, Woerden, The Netherlands).
IgG, IgA, IgM were measured by turbidimetry using an
Modular P800 (Roche, Almere, The Netherlands).
Anti-SSA and anti-SSB were determined by EliA (Thermo
Scientific, Uppsala, Sweden) and confirmed with ANA profile
immunoblot (EuroImmun, Lubeck, Germany). When the results
showed a discrepancy, a QUANTA Lite ELISA kit from INOVA
(San Diego, USA) was used for confirmation.
Bioassay for BAFF activity in serum and ELISA
To assess whether BAFF mRNA expression could be induced by
IFN type I activity in the serum of patients with pSS, THP-1
cells were cultured in 250Μl medium, as described previously.3
Serum (250Μl) from patients with pSS positive or negative for
the IFN type I signature was added to THP-1 cells and incubated
for 6 h. As positive control, recombinant human IFN-α (symbol
alpha instead of ‘A’) was added (5 ng/ml, Peprotech, London,
UK). HC serum was added as negative control and for blocking
anti-IFN type I receptor (PBL Interferon Source, Piscataway,
USA) was added (5Μg/ml).
BAFF protein in serum was assessed by ELISA (improved
Quantikine Human BAFF/BLyS, R&D Systems, Minneapolis,
USA).
Factor analysis
Expression levels of 11 IFN type I inducible genes were submit-
ted to a principal component analysis to identify correlated
groups of genes and reduce data complexity. The Kaiser–
Meyer–Olkin measure of sampling adequacy was 0.833 with
significant Bartlett’s test of sphericity (p<0.001). Eigenvalues
were derived to assess the amount of variance explained by
each component factor.
Statistical analyses
Statistical analyses were performed using SPSS 17.0 package.
When data were not normally distributed, values were
expressed as medians with IQRs and comparisons were made
using the non-parametric Mann–Whitney U test. For normally
distributed data, independent t test was used to compare
means. Correlations were assessed using either Pearson correl-
ation test for normally distributed data or Spearman’s Ρ when
data were not normally distributed. Linear regression was per-
formed on ESSDAI components with the IFN score as the
dependent variable. Differences were considered statistically sig-
nificant if p<0.05.
RESULTS
Increased IFN type I inducible gene expression in pSS
monocytes
In whole genome analyses of pooled monocytes, we previously
showed that 23 IFN type I inducible genes were upregulated in
Table 1 Demographics, laboratory and clinical characteristics of
participants
Controls (n=44) pSS (n=69)
Demographic characteristics
Female, n (%) 40/44 (91) 62/69 (90)
Mean age (years) 51±15 58±13
Disease duration (years) – 10.8±7.7
2002 American–European criteria – 4.2±0.4
Sjögren manifestations, n (%)
Ocular symptoms – 69/69 (100)
Oral symptoms – 66/69 (96)
Positive ocular tests – 53/69 (77)
Positive histopathology – 39/69 (57)
Positive salivary gland tests – 2/69 (3)
Anti-SSA – 58/69 (84)
Anti-Ro52 – 54/56 (96)
Anti-Ro60 – 47/56 (84)
Anti-SSB – 38/69 (55)
2002 American–European criteria: number of criteria fulfilled out of the six criteria
items.
Positive histopathology: focus score ≥1, defined as a number of lymphocytic foci
containing more than 50 lymphocytes per 4 mm2.
Positive salivary gland tests: sialography showing the presence of diffuse
sialectasias or salivary scintigraphy showing delayed uptake, reduced concentration
and/or delayed excretion of tracer.
pSS, primary Sjögren’s syndrome.
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Figure 1 (A) Gene expression of 11 interferon (IFN) type I inducible genes in patients with primary Sjögren’s syndrome (pSS) (n=69) and healthy
controls (HC) (n=44). To compare means the Mann–Whitney U test was applied. (B) Heat map showing gene expression of five interferon (IFN) type
I inducible genes in monocytes of patients with pSS (n=69) and HC (n=44). On the left the patients with pSS are depicted and subdivided into IFN
type I signature-positive patients and IFN type I signature-negative patients. On the right the HC are depicted. Red colour indicates high gene
expression. (C) Distribution of IFN scores in IFN type I signature-positive and -negative patients and HC. IFN type I-positive cases are depicted in
red. Blue lines depict medians. (D) Heat map showing gene expression of IFN type I inducible genes in monocytes of patients with pSS (n=24) at
two different time points (average period between two measurements 3.6±2.5 years). (E) No significant differences detected between two time
points using the dependent t test.
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pSS relative to HC.3 On the basis of their high, intermediate or
low levels of upregulation in the whole genome analysis, 11 of
the 23 IFN type I inducible genes were selected for analysis in
this study using RQ-PCR in CD14 monocytes and found to be
significantly upregulated in the pSS group relative to the HC
group (figure 1A). The 11 IFN type I inducible genes analysed
in the monocytes were: IFI27, IFI44L, IFIT3, IFITM1,
SERPING1, IFIT1, IFIT2, LY6E, IFI44, XAF1 and MX1.
Prevalence of ‘IFN type I signature’ in pSS monocytes
The results of a principal component analysis showed that a
subset of five genes (IFI44, IFI44L, IFIT3, LY6E and MX1)
explained 95% of the total variance of the 11 IFN type I indu-
cible genes. Given that the expression of these five IFN type I
inducible genes was not normally distributed, log transforma-
tions of expression values were performed and IFN scores were
calculated as described for SLE.27 The mean and SD level of
each IFN inducible gene in the HC group were used to stand-
ardise expression levels of each gene for each study subject. The
standardised expression levels were subsequently summed for
each patient to provide an IFN type I expression score.
The distribution of the IFN scores for the 69 patients was
bimodal with an overlap at a score of 10. We therefore set the
threshold for a positive IFN type I signature at 10. Adoption of
this threshold showed that 55% of pSS group had an IFN type
I signature and only 4.5% of the HC group (figure 1B,C).
To determine if the IFN type I signature possibly changes
over time, we assessed IFN scores at two different time points
in 24 patients with pSS. The average period between the two
measurement points was 3.6±2.5 years. A significant difference
in the scores over time was not detected (figure 1C,D), which
shows a stability of the signature over time.
Correlation of IFN type I signature with disease parameters
To investigate whether IFN type I activation, as reflected by a
high IFN score, is associated with disease activity, we assessed
ESSDAI disease activity scores in 38 patients with pSS.
Significant positive correlation was observed between IFN type I
scores and ESSDAI scores (r=0.458, p=0.003). The patients
with pSS were next stratified according to their IFN type I signa-
ture status (IFN score <10 vs IFN score ≥10) and the disease
activity scores were compared. Patients with a positive IFN type
I signature (IFN score >10) showed significantly higher ESSDAI
scores than those with a negative signature (figure 2A). The
high disease activity for patients with a positive IFN type I sig-
nature was mostly attributable to the presence of glandular,
cutaneous and haematological manifestations (table 2). Linear
regression analysis showed that the glandular, cutaneous and
articular manifestations—despite the non-suggestive p value in
the univariate analysis—were associated with high IFN type I
scores (Β coefficients with 95% CI, respectively: 5.90 (1.78 to
10.01), 5.00 (1.66 to 8.35) and 7.54 (2.38 to 12.71).
In addition to the ESSDAI, demographic, laboratory and
clinical parameters were collected. Comparison of IFN type I
signature-positive patients with IFN type I signature-negative
patients showed significant differences in anti-SSA autoanti-
bodies (anti-Ro52 and anti-Ro60), anti-SSB autoantibodies,
rheumatoid factor, C3, IgG, lymphocyte and neutrophil count
(table 3).
When patients were next stratified according to their auto-
antibody status (autoantibody positive vs autoantibody nega-
tive) for comparison of their IFN scores, patients with
autoantibodies showed higher IFN scores than patients
without autoantibodies (figure 2B). Rheumatoid factor and
higher IgG levels were more often present in the IFN signature-
positive patients than in IFN type I signature-negative patients
(figure 2C,D). C3, lymphocytes and neutrophils were lower in
IFN type I signature-positive patients with pSS (figure 2E–G).
No differences were found with respect to demographic charac-
teristics or medication status (table 3).
Correlation between BAFF expression and IFN type I signature
As already mentioned, a factor also known to be involved in
the pathogenesis of pSS and found to correlate with elevated
Figure 2 (A) EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores in interferon (IFN) type I signature-positive and -negative patients
with primary Sjögren’s syndrome (pSS) (n=38). (B) IFN scores in patients with pSS positive or negative for anti-SSA (both Ro52 and Ro60) and
anti-SSB (n=69). (C) Rheumatoid factor levels in IFN type I signature-positive and -negative patients with pSS (n=50). (D) IgG levels in IFN type I
signature-positive and -negative patients with pSS (n=68). (E) C3 levels in IFN type I signature-positive and -negative patients with pSS (n=46). (F)
Absolute lymphocyte levels in IFN type I signature-positive and -negative patients with pSS (n=42). (G) Absolute neutrophil levels in IFN type I
signature-positive and -negative patients with pSS (n=41). Independent t test was used to compare means in E–G, where horizontal bars represent
the means. Mann–Whitney U test was used to compare means in A–D, where horizontal bars represent the medians. In B medians and IQR are
depicted; ** represents p value<0.01 and **** represents p value <0.0001.
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serum levels of IgG, anti-SSA and anti-SSB is BAFF.16 BAFF
mRNA expression was increased in monocytes of the pSS
group relative to the HC group (figure 3A). Significant positive
correlation between the IFN score and BAFF mRNA expression
was also thus found (figure 3B).
We therefore next investigated if BAFF mRNA expression
could be induced in monocytes by IFN type I serum activity. A
bioassay was performed for this purpose using a THP-1 mono-
cytic cell line exposed to 50% by volume serum of patients
with pSS who were either positive or negative for the IFN type
I signature with and without a blocking antibody against
the IFN type I receptor. After incubation with serum from
IFN type I signature-positive patients (n=9), BAFF mRNA
expression was indeed induced in THP-1 cells. Blocking IFN
type I receptor diminished BAFF mRNA expression in THP-1
(figure 3C). Serum of IFN type I signature-negative patients did
not induce higher BAFF mRNA expression relative to that found
for the HC group.
To assess BAFF protein in serum, we performed an ELISA on
68 pSS samples and 42 HC. A statistical difference between
pSS and HC was seen (figure 3D). After stratification for posi-
tive versus negative IFN signature, however, no differences and
no correlations between the IFN scores and serum BAFF
protein were found (figure 3E). It is noteworthy that serum
Table 3 Comparison of patients with primary Sjögren’s syndrome with or without a positive interferon (IFN) type I signature
Variable N
IFN type I signature category
Positive Negative p Value
Demographics
Female gender, n (%) 69 34/38 (89) 28/31 (90) 0.908
Age (years) 69 56.7±12.5 59.5±13.3 0.376
Disease duration (years) 67 11.2±8.2 10.3±7.1 0.631
Laboratory parameters, n (%)
Anti-SSA, n (%) 69 37/38 (97) 21/31 (68) 0.001
Anti-Ro52, n (%) 69 35/38 (92) 19/31 (61) 0.002
Anti-Ro60, n (%) 69 34/38 (89) 13/31 (42) <0.001
Anti-SSB, n (%) 69 32/38 (84) 6/31 (19) <0.001
Rheumatoid factor (IE/ml) 50 25 (0, 100) 0 (0, 44) 0.048
C3 (g/l) 46 1.06±0.20 1.27±0.33 0.012
C4 (g/l) 46 0.18 (0.13, 0.20) 0.18 (0.14, 0.25) 0.261
IgG (g/l) 68 16.10 (13.15, 18.55) 11.60 (10.6, 15.00) 0.001
IgA (g/l) 54 3.20 (2.18, 4.25) 2.44 (1.69, 4.20) 0.179
IgM (g/l) 54 1.22 (0.78, 1.97) 1.36 (1.07, 1.67) 0.876
CRP (mg/l) 61 1.0 (0.0, 5.5) 3.0 (1.0, 7.0) 0.068
Hb (mmol/l) 60 7.95 (7.58, 8.33) 8.25 (7.78, 8.80) 0.159
Thrombocytes (×10E9/l) 51 219.5 (199.3, 284.8) 257 (221, 298) 0.190
Lymphocytes (×10E9/l) 42 1.32±0.55 1.85±0.57 0.005
Neutrophils (*10E9/l) 41 3.09±1.18 4.42±1.78 0.014
Medical treatment
Pilocarpine, n (%) 69 15/38 (39) 12/31 (39) 0.949
Plaquenil, n (%) 69 23/38 (61) 17/31 (55) 0.636
Corticosteroids, n (%) 69 3/38 (8) 1/31 (3) 0.412
Values are the mean±SD, median (25% quartile–75% quartile), or number (%) of patients, depending on whether the data are normally distributed or not, and whether the data
are continuous or dichotomous. When the data followed normal distribution, the independent t test was conducted; otherwise the Mann–Whitney U test was conducted.
CRP, C-reactive protein; Hb, haemoglobin.
Table 2 Comparison of interferon (IFN) scores for patients with primary Sjögren’s syndrome with or without different Sjögren’s Syndrome Disease
Activity Index (ESSDAI) features
ESSDAI feature
Present Absent
p ValuePatients (n) Median (IQR) Patients (n) Median (IQR)
Constitutional 6 6.28 (−1.74, 14.92) 32 5.19 (0.10, 13.97) NS
Lymphadenopathy – 38 5.19 (−0.26, 14.43) ND
Glandular 9 14.7 (4.10, 16.22) 29 2.65 (−1.16, 12.41) 0.029
Articular 16 8.73 (1.02, 14.94) 22 3.53 (−2.02,13.33) NS
Cutaneous 6 15.26 (11.85, 15.90) 32 3.53 (−2.02, 13.33) <0.001
Pulmonary – – 38 5.19 (−0.26–14.43) ND
Renal – – 38 5.19 (−0.26–14.43) ND
Muscular – – 38 5.19 (−0.26–14.43) ND
PNS 3 15.20 (−5.27–15.58) 35 4.40 (−0.16, 12.87) NS
CNS – – 38 5.19 (−0.26–14.43) ND
Haematological 2 16.09 (15.32, 16.85) 36 4.40 (−0.46,12.83) <0.001
Biological 20 10.21 (1.80, 14.94) 18 3.97 (−3.21, 12.88) NS
CNS, central nervous system; PNS, peripheral nerous system; NS, nonsignificant; ND, not determined.
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BAFF protein does not correlate with BAFF mRNA in mono-
cytes (figure 3F) and we also found in a smaller series that
BAFF mRNA in monocytes does not correlate with BAFF
mRNA in PBMCs (see supplementary online figure S1). This
suggests that production of BAFF is regulated differently in dif-
ferent circulating leucocytes; however, this needs further
investigation.
DISCUSSION
This study shows increased IFN type I activity for 55% of a
group of patients with pSS versus 4.5% for HC. The presence of
such an ‘IFN type I signature’ in monocytes of patients with
pSS was further shown to be associated with the ESSDAI, bio-
logical markers of activity and BAFF mRNA in monocytes.
BAFF expression could also be induced in cultured monocytes by
serum from patients with pSS with a positive IFN signature.
Taken together, these results suggest the following: a raised
level of IFN type I, present in the serum of a significant
number of patients with pSS, induces in monocytes overexpres-
sion of IFN type I inducible genes, among which is BAFF. After
production, this cytokine can induce polyclonal B cell stimula-
tion, which results in higher autoantibody production and
enhanced autoantigen–autoantibody reaction with complement
consumption. This scenario fits with our observation of a cor-
relation between the presence of a positive IFN type I signature
in monocytes and cutaneous manifestations in the ESSDAI
index. Moreover the biological domain of the ESSDAI includes
markers for B cell activation such as IgG, cryoglobulinaemia,
decrease of complement. Thus part of the association between
the IFN signature and the ESSDAI may be related to the role of
IFN type I in B cell activation.
A similar scenario resulting in vasculitis has been described
for SLE, systemic sclerosis and dermatomyositis. For subgroups
of these diseases, overexpression of IFN type I induced genes
has also been found. In SLE the overexpressed genes were asso-
ciated—similar to the findings of our studies—with nuclear
autoantibodies, glomerulonephritis and higher disease activ-
ity,28–30 again indicating the relationship between IFN activity
and B cell activation and immune complex vasculitis. While
these studies used PBMCs, we examined monocytes, as our
focus of previous work was on the role of monocytes and den-
dritic cells in pSS. The IFN type I signature which we report
for pSS monocytes is similar to the IFN inducible gene expres-
sion profile observed for pSS PBMCs.7 Furthermore, we assessed
the IFN type I signature in PBMCs of 12 patients with pSS
and six HC in supplementary analyses and found a high correl-
ation with the IFN type I signature identified for monocytes in
the same sample (see supplementary online figure S2).
There was surprisingly no correlation of monocyte activation
related to an IFN type I signature with other hallmarks of pSS
(ie, sicca symptoms and fatigue) (unpublished results). This is
surprising as there are different reports of sicca syndrome and
fatigue being induced by IFN type I treatment in patients with
hepatitis C and cancer.31 32 All patients scored positive for the
Figure 3 (A) B cell activating factor (BAFF) mRNA expression in monocytes in patients with primary Sjögren’s syndrome (pSS) (n=69) and
healthy controls (HC) (n=44). BAFF mRNA expression was determined by real time quantitative-PCR. (B) Correlation between interferon (IFN) type I
score and BAFF mRNA expression in monocytes in patients with pSS (n=69). (C) Induction of BAFF mRNA expression in THP-1 cells by incubation
with 50% serum of IFN type I signature-positive patients with pSS (n=9) and IFN type I signature-negative patients with pSS (n=7) in the presence
of a blocking IFN type I receptor antibody. Expression is relative compared with the mean expression in HC (n=8). (D) BAFF protein levels in serum
of patients with pSS (n=68) and HC (n=42) measured by ELISA. (E) Correlation between serum BAFF protein and IFN scores in patients with pSS
(n=68). (F) Correlation between serum BAFF protein and BAFF mRNA expression in monocytes of patients with pSS (n=68). The correlation
coefficients (r) and p values are shown. For correlations Spearman’s ρ correlation test was used and to compare means the Mann–Whitney U test
was used.
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sicca syndrome and these symptoms are not quantified in the
ESSDAI. Quantification using a Schirmer test or analogous test
is therefore merited in future studies. For fatigue the absence of
a correlation might be explained by the fact that we assessed
fatigue using the Visual Analogue Scale score and not the
Multidimensional Fatigue Inventory, which covers different
dimensions of fatigue. There are also reports that immune acti-
vation is not the only determinant of fatigue in patients
treated with IFN type I, but the induction of indoleamine
2,3-dioxygenase and the catabolism of tryptophan to quinolinic
acid at the expense of serotonin are also factors.33 More
in-depth research into the relations between fatigue and IFN
type I signature in pSS is thus essential.
Previously, we showed that although the number of plasma-
cytoid dendritic cells (pDC) was lowered in the blood of
patients with pSS—possibly owing to migration into the
glands—the remaining pDC showed increased activation.3
There are indications that pDC are the source of the high IFN
type I serum levels in SLE.34 pDC are the most powerful produ-
cers of IFN type I. Stimuli for the pDC to produce IFN type I
can be either exogenous (viral DNA/RNA) or endogenous, such
as immune complexes of nuclear antigens and antibodies (hall-
marks of pSS) which bind to FcγRIIa on the pDC, followed by
internalisation and binding to intracellular TLR7 and TLR9.35
This IFN type I production by pDC upon immune complex
binding might be an explanation for the association we found
between IFN type I scores and autoantibodies, IgG and lowered
C3. The absence of modification of the IFN type I signature in
patients treated with Plaquenil is surprising as Plaquenil is
known to inhibit the activation of intracellular TLR. This
might be explained by the fact that patients in our cohort are
using Plaquenil for years. Assessment of IFN scores in patients
before and after initiation of Plaquenil treatment in future
research could therefore be informative.
At this point two limitations on our study should be men-
tioned. First, the age of the patient group did not completely
match that of the HC group. In the statistical analysis we took
that into account and could not find a significant influence of
age on outcomes. A second possible limitation is the use of
multiple parameters for our correlations between the presence
of an IFN type I signature and clinical manifestations.
Although it is questionable whether a Bonferroni correction is
needed, when we applied such correction for n=22 (resulting
in a p value of 0.002), the differences in rheumatoid factor, C3
and lymphocyte and neutrophil counts lost significance. To
reach significance after such correction for C3, for example, 88
patients would have to be studied. Our study of 69 patients
with pSS is relatively large, but new validation studies with
larger numbers of participants are needed—also in light of the
fact that the ESSDAI was measured in only 38 patients and
laboratory parameters were not available for all patients.
To conclude, the findings of this study suggest that deter-
mining the presence of an ‘IFN type I signature’ in monocytes
of patients with pSS can be used to identify subgroups of
patients for specific treatment. Patients identified in such a
manner may benefit from treatment aimed at blocking the IFN
type I activity and thereby counteracting B cell activation and
autoantibody production.
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